PDF(Sci-hub)
Abstract：
OBJECTIVE: Following chemotherapy, induration may occur. This study was conducted to survey induration incidence and risk factors, and investigation for actual condition of induration.
METHODS: A cohort study was conducted for survey of incidence and risk factors, and a cross-sectional observation study was conducted to examine actual condition of induration. The sites of chemotherapy administration were recorded, and these were observed on the next treatment day. Clinical nurses judged the presence or absence of induration by palpation. The sites were observed using ultrasonography. To investigate the risk factors associated with the induration, logistic regression analysis was performed using independent variables based on univariate analysis or previous reports.
RESULTS: In total, 69 patients were analyzed. The induration incidence was 17.4%, and three abnormal conditions were confirmed: subcutaneous edema, thrombosis, and thickening of the vessel wall. Breast cancer, non-vesicant drug, vein diameter, and fosaprepitant use were included in the logistic regression model. Breast cancer: odds ratio (OR) 9.25; 95 CI 1.91.-44.71; non-vesicant drug: OR 1.37; 95 CI 0.13-14.95; vein diameter: OR 0.40; 95% CI 0.16-0.97; fosaprepitant use: OR 0.16; 95% CI, 0.18-10.32.
CONCLUSIONS: The induration incidence was 17.4%. Risk factors for induration following chemotherapy administration were breast cancer and smaller vein diameter. Abnormal cases of subcutaneous tissue were confirmed, including subcutaneous edema, thrombosis, and thickening of the vessel wall. Induration may be prevented by selecting larger diameter vessels using ultrasonography when catheterizing for chemotherapy.
METHODS: A cohort study was conducted for survey of incidence and risk factors, and a cross-sectional observation study was conducted to examine actual condition of induration. The sites of chemotherapy administration were recorded, and these were observed on the next treatment day. Clinical nurses judged the presence or absence of induration by palpation. The sites were observed using ultrasonography. To investigate the risk factors associated with the induration, logistic regression analysis was performed using independent variables based on univariate analysis or previous reports.
RESULTS: In total, 69 patients were analyzed. The induration incidence was 17.4%, and three abnormal conditions were confirmed: subcutaneous edema, thrombosis, and thickening of the vessel wall. Breast cancer, non-vesicant drug, vein diameter, and fosaprepitant use were included in the logistic regression model. Breast cancer: odds ratio (OR) 9.25; 95 CI 1.91.-44.71; non-vesicant drug: OR 1.37; 95 CI 0.13-14.95; vein diameter: OR 0.40; 95% CI 0.16-0.97; fosaprepitant use: OR 0.16; 95% CI, 0.18-10.32.
CONCLUSIONS: The induration incidence was 17.4%. Risk factors for induration following chemotherapy administration were breast cancer and smaller vein diameter. Abnormal cases of subcutaneous tissue were confirmed, including subcutaneous edema, thrombosis, and thickening of the vessel wall. Induration may be prevented by selecting larger diameter vessels using ultrasonography when catheterizing for chemotherapy.
摘要：
目的：化疗后，硬结可能发生。本研究旨在调查硬结发生率和危险因素，并对硬结的实际状况进行了调查。
方法：进行一项队列研究，调查发病率和危险因素，并进行了横断面观察研究，以检查硬结的实际情况。记录化疗的部位，这些都是在下一个治疗日观察到的。临床护士通过触诊判断是否存在硬结。使用超声检查观察该部位。为了调查与硬结相关的危险因素，使用基于单变量分析或既往报告的自变量进行logistic回归分析.
结果：总计，对69例患者进行分析。硬结发生率为17.4%，并确认了三种异常情况：皮下水肿，血栓形成,和血管壁增厚。乳腺癌,非起泡药，静脉直径,和福沙吡坦的使用被纳入逻辑回归模型。乳腺癌：比值比（OR）9.25；95CI1.91。-44.71；非起泡药：OR1.37；95CI0.13-14.95；静脉直径：OR0.40；95％CI0.16-0.97；福沙吡坦使用：OR0.16；95％CI，0.18-10.32。
结论：硬结发生率为17.4%。化疗后硬结的危险因素是乳腺癌和较小的静脉直径。证实皮下组织异常病例，包括皮下水肿,血栓形成,和血管壁增厚。在进行化疗时，可以通过使用超声检查选择更大直径的血管来防止持续时间。
方法：进行一项队列研究，调查发病率和危险因素，并进行了横断面观察研究，以检查硬结的实际情况。记录化疗的部位，这些都是在下一个治疗日观察到的。临床护士通过触诊判断是否存在硬结。使用超声检查观察该部位。为了调查与硬结相关的危险因素，使用基于单变量分析或既往报告的自变量进行logistic回归分析.
结果：总计，对69例患者进行分析。硬结发生率为17.4%，并确认了三种异常情况：皮下水肿，血栓形成,和血管壁增厚。乳腺癌,非起泡药，静脉直径,和福沙吡坦的使用被纳入逻辑回归模型。乳腺癌：比值比（OR）9.25；95CI1.91。-44.71；非起泡药：OR1.37；95CI0.13-14.95；静脉直径：OR0.40；95％CI0.16-0.97；福沙吡坦使用：OR0.16；95％CI，0.18-10.32。
结论：硬结发生率为17.4%。化疗后硬结的危险因素是乳腺癌和较小的静脉直径。证实皮下组织异常病例，包括皮下水肿,血栓形成,和血管壁增厚。在进行化疗时，可以通过使用超声检查选择更大直径的血管来防止持续时间。
